ClinicalTrials.gov
public full text
Public Domain
Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD)
Given that 5-HT3 receptors are indirect inhibitors of cortico-mesolimbic DA release, the 5-HT3 receptor antagonist ondansetron augmentation might potentially have efficacy in the treatment of resistant Obsessive Comulsive Disorder (OCD) patients on combined SRIs and antipsychotics.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Attaining and Maintaining Wellness in Obsessive-compulsive Disorder#993162
- Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients#857595
- Improving Obsessive-compulsive Disorder Treatments: from Lesions to Neuromodulation Targets#896265
- Addiction, Compulsion, and Persistent Temptation#757203
- Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.#848594
Record · ID 825022
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive